Genomics company Illumina (NASDAQ:ILMN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up ...

Illumina (NASDAQ:ILMN) reported first-quarter 2026 results that came in above its guidance range on revenue, margins, and earnings per share, supported by strength in clinical demand and ...

In the first quarter of fiscal 2026, reported on April 30, 2026, Illumina posted revenue of $1.09 billion, up 4.8% year over year, with GAAP operating margin rising to 19.2% and GAAP diluted EPS ...

With the strong start to the year, Illumina bumped up its guidance. It now expects revenue between $4.52 billion and $4.62 billion, up $20 million at the midpoint versus its prior guidance. It now ...

From Illumina to Nanopore to PacBio, getting high-quality sequencing data starts long before the run begins. Careful library prep, accurate quantification, platform-specific QC checks, and novel RNA ...

Management raised full-year guidance, with Dhingra stating, "We are raising our reported revenue guidance by $20 million... and now expect revenue of $4.52 billion to $4.62 billion" and "now expect ...

Whole genome sequencing (WGS) delivers deep insights into genetics, but its reliability depends on aligning coverage depth and uniformity with the study’s goals. Current research and practical guides ...

Wall Street analysts expect Illumina (ILMN) to post quarterly earnings of $1.05 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $1.08 ...

"Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present challenges: headwinds i ...

Cambridge-based Pharma sector innovator Bicycle Therapeutics has engineered a cash runway into 2030 on the back of cash and ...

Gaye Walker is joining the Florida Hospital Association (FHA) as vice president of Communications. In this role, she will ...

Driving community impact Providence integrates precision medicine to improve cancer care and close clinical quality gaps across its health system.